Oscient Pharmaceuticals Corporation OSCI - Abbott Gets Oscient Drug Canada License and AstraZeneca Says Has Full Confidence in Toprol XL Patents
Oscient Pharmaceuticals Corporation OSCI - Abbott Gets Oscient Drug Canada License and AstraZeneca Says Has Full Confidence in Toprol XL Patents
08/11/2006 - Pharmaceuticals Instruments industry news provided by Financial News USA (OTC: FNWU). Biotech drug maker Oscient Pharmaceuticals Corp. said Thursday it granted the Canadian unit of Abbott Laboratories Inc.'s (NYSE:ABT) rights to sell its anti-infective product Factive in Canada. Factive is approved in Canada to treat chronic bronchitis caused by bacteria over five days. Abbott Canada will launch the product in the coming months. "With 1,400 employees and a sales force experienced in building leading anti-infective brands, Abbott Canada is well-positioned to launch Factive in Canada," said Steven M. Rauscher, Oscient president and chief executive, in a statement. Biopharmaceutical Company MGI Pharma Inc. (Nasdaq:MOGN) said Thursday the U.S. Food and Drug Administration gave its leukemia drug Dacogen orphan drug status. The classification gives the company government incentives to further develop the drug, including up to seven years of marketing exclusivity. Dacogen has already received such status in the U.S. for Myelodysplastic Syndromes, or bone marrow disorders, and was approved for that use by the FDA May 2.
Drug maker AstraZeneca (NYSE:AZN) said that it continues to have full confidence in the intellectual property rights protecting its heart drug Toprol XL. It made the statement after the U.S. Food & Drug Administration granted approval to Novartis' Sandoz for 25 mg of metoprolol succinate, a generic form of Toprol XL, on August 1. The patent protecting Toprol XL expires in September next year. CytoDyn, Inc. (OTCBB:CYDY) has been invited to present clinical results from Cytolin® at the Treatment Horizons Forum of The AIDS Institute to be held on August 12, 2006 in conjunction with the XVI International AIDS Conference in Toronto. "CytoDyn will show how its targeted immune therapy reduces viral activity while avoiding the emergence of drug-resistant strains of HIV," according to Allen D. Allen, the Company's CEO.
08/11/2006 - Pharmaceuticals Instruments industry news provided by Financial News USA (OTC: FNWU). Biotech drug maker Oscient Pharmaceuticals Corp. said Thursday it granted the Canadian unit of Abbott Laboratories Inc.'s (NYSE:ABT) rights to sell its anti-infective product Factive in Canada. Factive is approved in Canada to treat chronic bronchitis caused by bacteria over five days. Abbott Canada will launch the product in the coming months. "With 1,400 employees and a sales force experienced in building leading anti-infective brands, Abbott Canada is well-positioned to launch Factive in Canada," said Steven M. Rauscher, Oscient president and chief executive, in a statement. Biopharmaceutical Company MGI Pharma Inc. (Nasdaq:MOGN) said Thursday the U.S. Food and Drug Administration gave its leukemia drug Dacogen orphan drug status. The classification gives the company government incentives to further develop the drug, including up to seven years of marketing exclusivity. Dacogen has already received such status in the U.S. for Myelodysplastic Syndromes, or bone marrow disorders, and was approved for that use by the FDA May 2.
Drug maker AstraZeneca (NYSE:AZN) said that it continues to have full confidence in the intellectual property rights protecting its heart drug Toprol XL. It made the statement after the U.S. Food & Drug Administration granted approval to Novartis' Sandoz for 25 mg of metoprolol succinate, a generic form of Toprol XL, on August 1. The patent protecting Toprol XL expires in September next year. CytoDyn, Inc. (OTCBB:CYDY) has been invited to present clinical results from Cytolin® at the Treatment Horizons Forum of The AIDS Institute to be held on August 12, 2006 in conjunction with the XVI International AIDS Conference in Toronto. "CytoDyn will show how its targeted immune therapy reduces viral activity while avoiding the emergence of drug-resistant strains of HIV," according to Allen D. Allen, the Company's CEO.
posted by Famous Quotations - Oscient Pharmaceuticals Corporation OSCI - Abbott Gets Oscient Drug Canada License and AstraZeneca Says Has Full Confidence in Toprol XL Patents
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home